BION Share Price Performance
CHF 0
-32.45 (-100.00%)
Price CHF 0
Fair ValueCHF 69.00
Share Pricen/a
BB Biotech AG Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
BION Community Narratives
AN
Fair Value CHF 69 37.9% undervalued intrinsic discount
Late Stage Biotech Focus And M&A Tailwinds Will Support Long Term Portfolio Outcomes
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value CHF 47.7 10.2% undervalued intrinsic discount
Patent Cliff Demand And Rate Volatility Will Pressure Biotech Portfolio Fundamentals
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Late Stage Biotech Focus And M&A Tailwinds Will Support Long Term Portfolio Outcomes
Catalysts About BB Biotech BB Biotech invests in a concentrated portfolio of biotech companies with a focus on late stage clinical and early commercial assets. What are the underlying business or industry changes driving this perspective?Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
CHF 69
37.9% undervalued intrinsic discount
Fair Value
Revenue
27.61% p.a.
Profit Margin
23.66%
Future PE
14.77x
Price in 2029
CHF 79.05
Patent Cliff Demand And Rate Volatility Will Pressure Biotech Portfolio Fundamentals
Catalysts About BB Biotech BB Biotech is an investment company that builds and manages a concentrated portfolio of biotechnology stocks with a focus on late stage clinical and early commercial companies. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 47.7
10.2% undervalued intrinsic discount
Fair Value
Revenue
-29.06% p.a.
Profit Margin
13.82%
Future PE
101.85x
Price in 2029
CHF 54.71
Trending Discussion
Recently Updated Narratives
AN
Late Stage Biotech Focus And M&A Tailwinds Will Support Long Term Portfolio Outcomes
Fair Value: CHF 69 37.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Patent Cliff Demand And Rate Volatility Will Pressure Biotech Portfolio Fundamentals
Fair Value: CHF 47.7 10.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Flawless balance sheet with solid track record and pays a dividend.
2 Risks
3 Rewards
BB Biotech AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 24, 2026
- 10.48
- 100.00%
- 93.93%
- 0%
About BION
- Founded
- 1993
- Employees
- 10
- CEO
- WebsiteView website
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Recent BION News & Updates
